Starling is pleased to now offer our patients access to select clinical trials that have the power to transform the lives of patients around the world. Benefits to patients who participate include:
- Receiving treatment for conditions that may not currently have therapeutic solutions.
- Access to medication that may not become available to patients for years or may be too costly at this point in time.
- Participation in screening studies that may change the face of cancer diagnosis in the future.
- Testing of blood, often free of charge.
- Compensation for participation.
- Playing a meaningful role in furthering medical knowledge and potentially life-saving measures.
We currently are accepting patients for two clinical trials and will be adding more trials over time. Based on specific criteria, your Starling provider will determine if you are a candidate for a trial. A member of our research team will then reach out to you to discuss what you could expect if you chose to participate.
Study 1: Blood test to screen patients for the presence of colorectal cancer (CRC)
This trial examines whether a new blood test can screen for colorectal cancer rather than a screening colonoscopy. During an office visit, the provider identifies a patient who is already scheduled for a screening colonoscopy. The patient would then give a blood sample before undergoing the screening colonoscopy.
Patients who participate in the study will be compensated for their participation. Patients are eligible for the study regardless of the location where they will have the colonoscopy.
Study 2: Blood test to screen for multiple types of cancers
This study involves analysis of a blood sample to screen for the presence of colon, breast, or lung cancer. During an office visit, the provider identifies patients who meet the following:
- Patients referred for colonoscopy because of positive findings in FIT, FOBT, Cologuard, or Epi proColon, or were just diagnosed with colon cancer
- Patients that have an abnormal Low Dose CT of the chest, or were just diagnosed with lung cancer
- Patients that had suspicious screening mammograms, or were just diagnosed with breast cancer
The patient would then be asked to give a blood sample to check for certain screening markers. Patients who participate in the study will be compensated for their participation.
If you believe you are a candidate for either study, discuss with your Starling provider. Or, reach out to our Clinical Research Coordinator: Kristine Calabrese.
Clinical Research Coordinator
(860) 224-6266 x6616